Dilazep
Dilazep is a vasodilator that acts as an adenosine reuptake inhibitor.[1][2]
Clinical data | |
---|---|
Trade names | Comelian Kowa |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C31H44N2O10 |
Molar mass | 604.697 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
It is used for the treatment of cardiopathy and renal disorders.[3]
Synthesis
The reaction of bis-(3-hydroxypropyl)-ethylene diamine (1) with 1-Bromo-3-chloropropane (2) gives homopiperazine [19970-80-0] (3). Esterification by reaction with 3,4,5-Trimethoxybenzoyl Chloride [4521-61-3] (4) completed the synthesis of Dilazep (5).
See also
- Hexobendine, a drug with similar chemical structure
References
- Deguchi H, Takeya H, Wada H, Gabazza EC, Hayashi N, Urano H, Suzuki K (September 1997). "Dilazep, an antiplatelet agent, inhibits tissue factor expression in endothelial cells and monocytes". Blood. 90 (6): 2345–56. doi:10.1182/blood.V90.6.2345. PMID 9310485.
- PubChem. "Dilazep". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-08-18.
- "Pharmaceuticals". Kowa Company Ltd.
- GB1107470 idem Herbert Arnold, Kurt Pahls, Rolf Rebling,Norbert Brock, Hans-Dieter Lenke, U.S. Patent 3,532,685 (1970 to Asta Werke Ag Chem Fab).
- Schlögl, K., Schlögl, R. (1964). "Über pharmakodynamisch wirksame 3,4,5-Trimethoxybenzoate und verwandte Ester von symmetrischen Bis-hydroxyalkylpiperazinen und-dialkylpolymethylendiaminen". Monatshefte für Chemie. 95 (3): 922–941. doi:10.1007/BF00908805.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.